Understanding brain activity changes during ketamine treatment for psychiatric disorders
HNC: Human Neural Circuits Electrophysiology During Cognition
This study is testing how ketamine changes brain activity in patients with psychiatric disorders to better understand its benefits and side effects during treatment.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT05962424 on ClinicalTrials.gov |
What this trial studies
This research aims to investigate how ketamine affects brain activity and leads to dissociative symptoms in patients undergoing antidepressant therapy. By recording neural circuits during cognitive tasks, the study seeks to uncover the mechanisms behind the therapeutic effects of ketamine and its side effects. The focus is on patients in clinical neuro inpatient units at Stanford Medical Center, where the effects of ketamine will be closely monitored and analyzed.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are currently in clinical neuro inpatient units at Stanford Medical Center.
Not a fit: Patients with a lifetime history of psychotic disorders, pregnant or nursing females, or those who have had an adverse response to ketamine may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of ketamine's effects, leading to improved treatment strategies for psychiatric disorders.
How similar studies have performed: Other studies have explored ketamine's effects on brain activity, but this specific approach to understanding dissociation during treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient in clinical neuro inpatient units at Stanford Medical Center * Age \>18 years old * Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex) Exclusion Criteria: * Lifetime psychotic disorder * Pregnant or nursing females * Prior adverse ketamine response * Use of ketamine in past 7 days
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Karl Deisseroth, MD, PhD — Stanford University
- Study coordinator: Arjay Cordero
- Email: arjayc@stanford.edu
- Phone: 650-580-9000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.